Apogee Therapeutics to be Acquired by AbbVie for $10.9 Billion in All-Cash Deal
APGE has more than doubled off its 52-week low of $34.34 on elevated volume (32× avg).
Summary
Apogee Therapeutics has entered into a definitive agreement to be acquired by AbbVie for $135.11 per share in cash, a transaction valued at approximately $10.9 billion. This filing initiates the proxy solicitation process for shareholder approval of the merger.
Key Events · M&A and Partnerships · APGE
-
Acquisition Agreement Announced
Apogee Therapeutics will be acquired by AbbVie Inc. for $135.11 per share in an all-cash transaction.
-
Significant Transaction Value
The deal is valued at approximately $10.9 billion, representing a ~49% premium to Apogee's closing price on June 18, 2026.
-
Strategic Integration
AbbVie aims to integrate Apogee's immunology pipeline, including the lead asset zumilokibart, leveraging AbbVie's extensive development and commercial capabilities.
-
Shareholder Benefits
All Apogee equity compensation will accelerate and become fully vested upon closing, with shareholders receiving cash for their shares.
Analysis · APGE · Life Sciences
This DEFA14A filing serves as soliciting material for the proposed acquisition of Apogee Therapeutics by AbbVie Inc. for $135.11 per share in cash, valuing the company at approximately $10.9 billion. This transaction, which represents a significant premium for shareholders, marks a complete change in the company's future, integrating its promising immunology pipeline, particularly zumilokibart, into AbbVie's global capabilities. The acquisition is subject to shareholder and regulatory approvals and is expected to close in the third quarter of 2026. The offer price is above the current trading price and the 52-week high, indicating a favorable outcome for existing shareholders.
At the time of this filing, APGE was trading at $132.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $34.34 to $133.00. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.